TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02765581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
Study: NCT04216264

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard response
Description: Parents pick from a menu of behavior changes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Targeted response
Description: Stepped up phone interaction with parents based on menu of behavior changes
Study: NCT00818701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose Nesiritide
Description: Nesiritide infusion 0.005ug/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nesiritide, Sildenafil
Description: Nesiritide 0.005ug/kg/min Sildenafil 50 mg
Study: NCT02901392

Intervention type: PROCEDURE
Intervention: AMS-800
Description: Artificial urianry sphincter

Intervention type: PROCEDURE
Intervention: ADVANCE/ADVANCEXP
Description: Male sling

Intervention type: PROCEDURE
Intervention: VIRTUE
Description: Male sling

Intervention type: PROCEDURE
Intervention: INVANCE
Description: Male sling
Study: NCT00861562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imescard water smartweed composed pills
Description: 01 pill at every 8 hours for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imescard water smartweed composed pills
Description: 01 pill at every 8 hours for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
Study: NCT02559804

Intervention type: OTHER
Intervention: survival and late effects
Description: survival and late effects
Study: NCT02934100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Master 300
Description: Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skanlab 25 BODYWAVE
Description: Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVO US13 CosmoGamma
Description: Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LASER CTL1106MX
Description: Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching
Study: NCT03125616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
Study: NCT02079961

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified yoghurt
Description: A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCC
Description: Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC
Description: Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health.
Study: NCT04150848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion Regulation Therapy (GET)
Description: Six sessions delivered individually over 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Psychotherapy (ISP)
Description: Six sessions delivered individually over 8 weeks
Study: NCT00387790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo focal cranial radiotherapy
Study: NCT01936441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia (CBT-I)
Description: See Experimental Arm Description

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Menopause Education Control (MEC)
Description: See Experimental Arm Description
Study: NCT00706303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported self management training and support
Description: Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Supported self management training and support
Description: Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
Study: NCT00737815

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate: a total of 500 mg elemental magnesium
Description: 500 mg elemental magnesium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo pill
Study: NCT03658590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: a prefilled syringe with two milliliters of distilled water intravenously.
Study: NCT03929380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squat protocol
Description: 60% of 1RM weight for 100 squat reps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squat protocol
Description: 60% of 1RM weight for 100 squat reps
Study: NCT02840591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Study: NCT05326269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terbutaline
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: Subcutaneous injection
Study: NCT01043367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deprexil
Description: One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
Study: NCT02110836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose ingestion
Description: Glucose ingestion during exercise at 1.8 g/min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose ingestion
Description: Sucrose ingestion during exercise at 1.8 g/min
Study: NCT01046838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 40 mg three times daily for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet 3 times daily for 9 weeks
Study: NCT01497288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFS (Intranasal Fentanyl Spray)
Description: Intranasal Fentanyl Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFS (Intranasal Fentanyl Spray)
Description: Intranasal Fentanyl Spray
Study: NCT03479164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra Low-Dose CT
Description: Ultra Low-Dose CT
Study: NCT01719497

Intervention type: DRUG
Intervention: [C-11]OMAR
Description: PET radioligand

Intervention type: DRUG
Intervention: [C-11]OMAR
Description: PET radioligand

Intervention type: DRUG
Intervention: [C-11]OMAR
Description: PET radioligand

Intervention type: DRUG
Intervention: [C-11]OMAR
Description: PET radioligand
Study: NCT03446196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid replacement based on MOSTCARE up
Description: Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV \> 12%
Study: NCT04192383

Intervention type: RADIATION
Intervention: Cyberknife stereotactic radiosurgery
Description: Hypofractionated stereotactic radiosurgery
Study: NCT02433951

Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Maximal exercise test with ergospirometry.

Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Maximal exercise test with ergospirometry.

Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Maximal exercise test with ergospirometry.
Study: NCT03134703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
Study: NCT03110913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intakes
Description: Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
Study: NCT02663713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 60mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 60mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily
Study: NCT02896413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 0.9% saline infusion
Study: NCT04374942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
Study: NCT03574012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Use Fitbit tracker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Use Fitbit tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive general health and fitness information from clinician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05855148

Intervention type: PROCEDURE
Intervention: Enlistment For Lung Transplant
Description: All included patients are enlisted for lung transplantation
Study: NCT04013685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orca-T
Description: an allogeneic stem cell and T-cell immunotherapy biologic
Study: NCT03275350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Injectable Suspension
Description: Six monthly injections of extended-release naltrexone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment for opioid use disorder provided at each HIV clinic
Study: NCT02074410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03828578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy
Description: High flow oxygen therapy delivered via Airvo2
Study: NCT04504552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
Study: NCT02191865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Soft gelatine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Soft gelatine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Soft gelatine capsule
Study: NCT04335136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhACE2 APN01
Description: Patients will be treated with APN01 intravenously twice daily (BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: Patients will be treated with placebo intravenously twice daily (BID).
Study: NCT00787618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg Proellex
Description: Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg Proellex
Description: Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg Proellex
Description: Single dose
Study: NCT00778661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin 400mg + clovalunic acid 57.5mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin 400mg + clovalunic acid 57.5mg tablets
Study: NCT02350478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive placebo orally once daily for 12 weeks.
Study: NCT00311129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
Study: NCT02354196

Intervention type: PROCEDURE
Intervention: CCTA
Description: CT of heart to assess coronary disease
Study: NCT03171467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Study: NCT04203186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone-proguanil
Description: Malaria standard treatment regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone-proguanil
Description: Malaria standard treatment regimen
Study: NCT01655004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.